Device Identity and Digital Claims: US–China Governance in 2026

TL;DR

A device identifier and a promotional claim answer different questions. US UDI rules specify information for identifying a device, while intended-use and premarket rules govern the implications of what a firm says about it [1] [2] [3] [4]. China's UDI declaration service likewise places product-identifier submission with the registrant or filing entity; advertising authorization follows its separate review rules [5] [6].

China's SAMR Order No. 21 remains the current advertising-review measure as of the November 6, 2026 evidence cutoff. The May 15, 2026 consultation draft would change several digital-channel and administrative provisions, including live-stream replays and permit validity; this report distinguishes proposed changes from current obligations [7] [8] [9]. The separate advertising-citation guide concerns substantiation and attribution, rather than permission to promote every cited scientific claim [10].

For a cross-border content team, the useful operating decision is to connect each published model and claim to its authoritative record, approval owner and release history. Six public FDA letters illustrate the evidence investigators actually used. A historical GUDID sample and a bounded warning-letter screen inform the supporting data work; neither measures industry-wide compliance or the effectiveness of a marketing-control system [11] [12].

Product Identity Needs an Evidence Owner and a Claims Review

Map the US and Chinese systems at the product level, with jurisdiction-specific evidence. A US UDI identifies a device and links to descriptive information. Under 21 CFR 830.310, GUDID submission includes specified device attributes, including the applicable premarket submission number or exemption statement. Intended use is a separate issue: labeling claims, advertising and other relevant statements can be evidence of objective intent under 21 CFR 801.4 [1] [2] [3]. The applicable premarket pathway and the significance of a change must be assessed under the relevant rules; that assessment follows the actual claim and evidence alongside the identifier [4].

NMPA's 2019 UDI system rules and its product-identifier declaration service establish a Chinese submission framework for registrants and filing entities [5] [6]. For advertising within the scope of SAMR Order No. 21, assess the actual content and review requirements against the applicable product evidence and the measure [7]. A proposed change in the 2026 draft must remain a planning consideration until adoption and implementation are verified [8] [9].

Our recommendation is a field-level reconciliation record. Keep the identifier, model/version, authorized purpose, labeling revision, Chinese registration or filing evidence, US premarket evidence and published content version as linked but separately owned records. The client's regulatory or medical/legal review function decides the permissible claim. Content operations maintains the approved wording and its implementation across channels. This is a proposed operating arrangement.

The worksheet distinguishes an identity question from a permission question. A device can have a populated brand, company and DI field while its proposed clinical claim still requires review. Conversely, an optional description field can be blank without proving a violation. The FDA Data Elements Reference Table describes device description as recommended and important for identification and adoption; it is a useful place to differentiate similar records, with links allowed as supplementary information [13]. The operational opportunity is to improve the quality and traceability of the reader's product information, with its actual regulatory scope intact.

What the Historical GUDID Sample Shows

The archived openFDA device/udi export is dated July 7, 2026. Its local normalized census records 5,083,948 rows across 21 CSV partitions. We analysed the first four partitions in file order, comprising 1,000,000 records. This is a bounded, ordered sample, not a random sample and not a census of the current database [11].

Brand name, company name and DI were populated in 1,000,000 sampled records. Model/version was populated in 999,995; its percentage rounds to 100.00%, but five values were absent. Device description was populated in 796,479 records (79.65%) and product-code data in 993,957 (99.40%). These are field-population observations in this export, not determinations of submission completeness or noncompliance [11]. The recommended description field can help a downstream reader distinguish otherwise similar records, which is a reason to review its usefulness rather than label every blank as a defect [13].

Premarket submission information and sterilization-related information require the relevant source structures. A compliance determination requires examination of the source submission and applicable rule, beyond this flat-file projection. Under 830.310(b)(11), the applicable premarket submission number or exemption statement is required. Assess that obligation using the source submission and applicable requirements [2].

Before implementing a Chinese UDI data connection, obtain the current manual and schema through NMPA’s declaration service and record the version used for testing. This report addresses product identity and claim governance rather than certifying a particular API payload.

FDA Letters: A Bounded Screen and Six Checkable Cases

The July 31, 2026 archive contains 3,643 indexed FDA letters, including 224 CDRH letters with issue dates from January 25, 2021 through June 15, 2026. These are the boundaries of the archived input, not FDA's entire enforcement history or the current online census [12]. Letters describe different regulated activities. Recipient roles require the letter’s recipient and activity context.

We therefore used the FDA index's subject field for a narrower, reproducible screen: CGMP, QSR, Quality System, Failure to Register and List, or Medical Device Reporting. It selects 126 CDRH letters, split into 66 issued in 2021–2024 and 60 issued in 2025–2026 within this snapshot. This is a manufacturing, registration and reporting subject screen. The groups are disjoint, and channel categories can overlap within a letter [12].

Communication Terms in the Screened Letters

The chart counts regular-expression matches for channel words after attempted letter-body and agency-URL cleanup. Determining an unlawful advertisement, its role in an action or its importance requires reading the underlying letter. The practical use is to identify where a reviewer may need to inspect the underlying evidence, then read the actual letter [12].

Regulatory Terms in the Same Screened Letters

The screen still detects Part 812 terms in 37 of the 126 subject-selected letters. That directly demonstrates why subtracting every IDE-term match from the archive to construct a "manufacturer denominator" would be invalid. We make no claim that the changes between these groups measure a shift in FDA enforcement priorities. Index selection, subject composition and the meaning of a word match constrain that interpretation [12].

Granular Analysis of Six 2025–2026 CDRH Warning Letters

Six enforcement actions from 2025 and 2026 illustrate the evidentiary mechanisms CDRH investigators employ:

1. BlephEx, LLC (MARCS-CMS 725861, June 3, 2026) — Website Video Timestamps Exceeding Class I 510(k) Exemption Boundaries Coupled With Complete GUDID Omission: Following an inspection of its Brentwood, Tennessee facility (October 30 to November 19, 2025) and review of www.blephex.com, CDRH cited BlephEx for marketing the BlephEx Powered Eyelid Cleaning Sponge, OptiVize Ophthalmic Battery-Powered Electrolysis Unit, and OptiVize Ophthalmic Forceps without premarket clearance and without GUDID registration [14]. In 2017, the firm submitted a Section 513(g) request proposing regulation under 21 CFR 878.4820 (product code PYU, surgical instrument motors and accessories, Class I exempt from 510(k) subject to 21 CFR 878.9 limitations), explicitly stating the product was intended solely for eyelid hygiene and "not for the cure, treatment or mitigation of any disease or condition" [14]. During the 2025–2026 review, CDRH cited embedded videos on https://www.blephex.com/blephex-procedure, including a news video promoting BlephEx as a new "treatment option called BlephEx" for blepharitis and an 18-minute 7-second clinical procedure video where the company president recommended the device for "dry eye and blepharitis patients" (timestamps 0:20–0:21), "opening up the meibomian glands, [which means] we have better oils, therefore better vision" (timestamps 0:54–0:58), and "pre-cataract and pre-LASIK patients" (timestamps 0:48–0:49) [14]. These therapeutic disease claims exceeded the Class I exemption boundaries under 21 CFR 878.9, rendering the device adulterated under Section 501(f)(1)(B) and misbranded under Section 502(o) and 21 CFR 807.81(a) [4] [14]. Simultaneously, CDRH cited BlephEx under Section 502(t)(2), 21 CFR 801.20(a), 21 CFR 830.300(a), and 21 CFR 830.320(b) for failing to submit required UDI information to GUDID for all three marketed devices [1] [2] [14].
2. Happiest Baby, Inc. (MARCS-CMS 718306, June 15, 2026) — E-Commerce Distribution of Unauthorized Dimensional SKUs Outside De Novo Authorization: Following a July 2025 inspection in Los Angeles, California and review of https://www.happiestbaby.com (reviewed May 7, 2026), CDRH cited Happiest Baby under Section 501(f)(1)(B), Section 502(o), and 21 CFR 807.81(a)(3)(i) and (ii) [15]. While FDA granted De Novo authorization (DEN210039) for the SNOO Smart Sleeper bassinet paired with three sleep sack sizes—Small (5–12 lbs, 49 cm length by 23 cm chest width), Medium (12–18 lbs), and Large (18–25 lbs)—the firm distributed an unauthorized X-Small Sleep Sack SKU marketed on its website for infants weighing 4–8 lbs (measuring 44 cm long by 21 cm wide) originating from a beta program, alongside an unapproved X-Large sack [15]. CDRH determined that marketing the X-Small SKU for infants overlapping the 5–8 lbs range constituted a significant design modification that could "compress vital organs, limit diaphragmatic movement, and result in respiratory compromise", requiring a new 510(k). The 4-lb lower limit also extended the intended patient population to infants as light as 4 lbs, cited under 807.81(a)(3)(ii) [4] [15]. The letter also cited quality system violations under 21 CFR Part 820 and failure to report a removal under Section 502(t)(2) and 21 CFR Part 806 [15].
3. BMC Medical Co., Ltd. (MARCS-CMS 725759, May 20, 2026) — Commercial Rebranding (G3 to G3X) Coupled With Unsubmitted Firmware Algorithms and Hardware Modifications: Linked to an inspection of US distributor 3B Medical, Inc., CDRH cited China-based BMC Medical Co., Ltd. (510(k) holder for the Luna CPAP and Auto CPAP System cleared under K153387) under Section 502(o) and 21 CFR 807.81(a)(3)(i) for introducing a modified model commercially branded as the G3X APAP (model G4600) without premarket notification [16]. Engineering verification documentation (nP3_Product System Verification Report_G3-2.11.01, approved March 12, 2025) revealed that BMC Medical had updated the firmware (version 2.11.01) to introduce three respiratory event detection algorithms—Flow Limitation, Respiratory Effort-Related Arousals (RERA), and Periodic Breathing—to distinguish central from obstructive hypopnea, while altering gas-pathway sound-abatement materials and adding a new Printed Circuit Board Assembly (PCBA) chip [16]. Commercializing a modified device under a new model name (G3X APAP) with altered event-recognition features and materials without 510(k) clearance rendered the device misbranded under Section 502(o) [4] [16].
4. Diasol, Inc. (MARCS-CMS 719460, January 29, 2026) — Inspectional Intended-Use Expansion and Omitted UDI Labeling: Demonstrating that FDA identifies labeling and clearance violations during establishment inspections with the evidence coming from the inspected product and labeling, CDRH cited Diasol, Inc. for distributing 50% and 20% Citric Acid solutions labeled for cleaning, decalcification, and heat disinfection of hemodialysis machines [17]. Although Diasol held 510(k) clearance K020231 for dialysate concentrate in sorbent-regenerated dialysis, K020231 did not cover machine disinfection, triggering adulteration (Section 501(f)(1)(B)) and misbranding (Section 502(o) and 21 CFR 807.81(a)(3)(ii)) citations [4] [17]. Concurrently, finished-device acceptance records revealed that Diasol released nine potassium DHRs and 15 of 23 calcium DHR batches failing electrolyte specifications (21 CFR 820.80(d)) [17]. CDRH cited Diasol under Section 502(c) and 21 CFR 801.20(a) because labels for Citrisol Powder 45125-10, CitriSol 100225-10, Diasol 100225-10, Citric Acid 50%, Diasol 10000-25, and Dryasol 45225-10 lacked plain-text and machine-readable UDI carriers [1] [17].
5. Physitemp Instruments, LLC (MARCS-CMS 717394, November 12, 2025) — Missing Plain-Text and AIDC UDIs Across Multi-Probe SKU Families: CDRH cited Physitemp Instruments under Section 502(c), Section 502(t)(2), 21 CFR 801.20(a), and 21 CFR 801.40(a)(1)–(2) because ten clinical temperature monitoring consoles and probes (models TH-5, TH-5/AOP, TH-8, TH-8/AOP, OT-1, ESO-1, RET-1, MT-D, SST-1, and SST-2) lacked both readable plain-text UDIs and machine-readable AIDC technology on product labels [1] [18]. A query of GUDID confirmed that no device identifiers had been submitted for the Physitemp labeler [2] [18]. CDRH coupled these UDI misbranding charges with citations under 21 CFR 820.75(a) for an unvalidated sterilization method described in guides supplied to customers, as well as unvalidated laser welding [18].
6. Technological Medical Advancements LLC (MARCS-CMS 712715, September 26, 2025) — Unapproved High-Power Laser Indications and Missing UDI Labeling: CDRH cited Technological Medical Advancements LLC under Section 501(f)(1)(B) and Section 502(o) for marketing the Diowave 250 WLS and Diowave 100 WLS High Power Laser Systems on www.diowavelaser.com (reviewed July 1, 2025) and in brochures for claims about no-heat “stealth micro-pulse,” deep penetration and healing living tissue, including peripheral neuropathy, wound care, postsurgical pain and disc pathology, exceeding K121363’s infrared-lamp clearance under 21 CFR 890.5500 for topical heating and specified minor muscle and joint pain relief [4] [19]. Separately, CDRH cited the firm under Section 502(c), 21 CFR 801.20(a), and 21 CFR 801.40(a) because product labeling for the Diowave Pure Pulse Laser System lacked required device identifiers [1] [19].

Use each letter to define the evidence request

Diasol illustrates three separate identification questions. The letter’s label findings concern whether the required plain-text and AIDC UDI carriers appeared on the specified products. Its GUDID finding names Citrisol Powder 45125-10, Citric Acid 50%, and Dryasol 45225-10. The machine-disinfection claim raises the separate intended-use and clearance issue. A content review should therefore ask which product and presentation are in scope, which labeling was inspected, what the database submission covered and which use the actual premarket decision supports. Treating all three as one website-description defect would lose the letter’s distinction [17].

BMC’s letter also goes beyond naming consistency. In addition to the firmware, materials and hardware changes, FDA addresses correction/removal reporting under Part 806. A model-name update can signal the need to retrieve the change record; the engineering modifications and reporting facts determine the questions it must answer. A proposed content handoff should link to the approved product revision and the client’s regulatory decision, so the published model table does not become the only available description of what changed [16].

Physitemp’s UDI labeling and GUDID findings coexist with process-validation issues. The customer sterilization guides communicated a method whose validation FDA challenged, while laser welding concerned manufacturing. That distinction matters for the evidence owner: an editor can maintain the released guide and its version, but the underlying validated method and device-processing instructions require the responsible technical and quality functions. The appropriate content control is a traceable approved source and escalation path, with no claim that a publishing tool validates sterilization [18].

Happiest Baby shows why population and dimensions should remain structured facts in a release package. A SKU extension can alter the intended population or securement behavior. The letter separately discusses the 4-lb population change, dimensional changes and the affected system. A reviewer needs those facts beside the proposed commerce page; a familiar product family name or an existing De Novo number alone cannot resolve a changed SKU’s authorization status [15].

FDA Guidance Status: SIUU and General Wellness

Two FDA guidance documents frame different communication boundaries. Happiest Baby’s letter expressly cites General Wellness in its Hospital Bundle analysis; BlephEx does not address SIUU. Their recommendations and scope need to be read alongside each letter’s actual product and allegations [20] [21].

SIUU: read the displayed limitation and later approval record together

FDA issued its revised final procedural SIUU guidance in January 2025 for certain firm-initiated scientific communications to healthcare providers about unapproved uses of approved or cleared products. It describes an enforcement policy concerning the dissemination of a communication standing alone as evidence of a new intended use, with the recommendations and scope set out in the document. It creates no binding safe harbor, and the underlying intended-use rule remains 21 CFR 801.4 [20] [3].

At the November 6, 2026 evidence cutoff, the FDA guidance page and January PDF still display a “Not for Current Implementation” limitation concerning information collections in Q2, Q4 and Q5. A later record also matters: the September 25, 2025 Federal Register notice, 90 FR 46225, includes docket FDA-2008-D-0053 and lists approval of OMB control numbers 0910-0686 and 0910-0485 through July 31, 2028. Those are the drug-product communication and medical-device labeling collections relevant to the guidance’s PRA discussion. The later approval notice and the guidance’s unrevised display coexist in the public record; this article leaves that implementation-status discrepancy explicit. A content team should obtain an authoritative current position before relying on an operative SIUU workflow. The related VayoMed SIUU status report examines that evidence trail [20] [22].

For planning, the text’s recommendations can be read accurately without turning them into statutory mandates. Q1 asks for scientifically sound, clinically relevant source publications, assessed against existing scientific knowledge at each dissemination. Q4 recommends unaltered, unabridged journal reprints: an independently managed journal with an expert editorial board and a public conflicts policy, expert peer review, and general availability through independent distribution channels. The proposed interpretation needs support from the paper’s actual evidence [20].

Q2 recommends nine information elements. The following is a paraphrase of that list; the source contains qualifications for particular reference resources:

1. A statement that FDA has not approved the described use and has not established the product’s safety and effectiveness for that use.
2. A statement of the FDA-approved uses, including labeling limitations.
3. Relevant limitations, restrictions, cautions, warnings or precautions in FDA-required labeling about the unapproved use.
4. Current FDA-required labeling, or an appropriate mechanism to obtain it.
5. Contraindications in the FDA-required labeling.
6. Relevant serious, life-threatening or fatal risks in labeling or known to the firm; where a REMS exists, its existence and goals.
7. Known relevant author, editor or contributor employment, consulting or compensation relationships with the firm at the time of the contribution.
8. For source publications focused primarily on particular studies, missing material design, methodology and results; material limitations; and conflicting conclusions from other scientifically sound studies, with their citations.
9. A source publication’s date where absent from the publication or citation. [20]

Q3 recommends clear, prominent disclosures and separation from promotional communications. Online, the example calls for a separate webpage, clearly identified with the recommended disclosures, and recommends against direct links from promotional pages about approved uses to SIUU pages. A character-limited platform that cannot accommodate the disclosures should not host the SIUU communication; it can direct HCPs to one through an appropriate product-neutral statement. The online example specifies separation, disclosures and linking behavior [20].

For an audiovisual asset, Q3 recommends presenting the disclosures in audio and text at the same time using the same words. The medium therefore affects whether the communication can convey the necessary context. A short clip derived from a longer scientific presentation needs its own assessment: removing limitations or disclosures can change what the audience receives. This is the practical reason to review the released asset, rather than assume that approval of a long source presentation covers every extract [20].

The BlephEx letter does not address SIUU. It documents disease-treatment claims on a commercial procedure page, illustrating the kind of material the guidance recommends separating from scientific exchange. The legal analysis in the letter rests on the actual device, its exemption limitations, claims and cited premarket provisions. Under 801.4, labeling and advertising claims can supply evidence of objective intent; the presence of a study or a clinician’s interview does not decide that assessment on its own [14] [3] [20].

General wellness: intended use and low risk are separate conditions

FDA’s January 6, 2026 General Wellness: Policy for Low Risk Devices covers low-risk products meeting its general-wellness intended-use conditions. One category concerns maintaining or encouraging a general state of health without reference to a particular disease, including sleep management, physical fitness or stress management. The other concerns healthy-lifestyle uses associated with reducing the risk or impact of certain chronic conditions where that association is well understood and accepted [21].

Low risk is a separate part of the policy. Invasiveness, implantation and technologies posing safety risks, such as lasers or radiation exposure, belong in that risk assessment. A disease-diagnosis algorithm or active treatment claim also needs assessment of intended use; describing those issues collectively as one list of risky hardware would obscure the policy’s two conditions [21].

The Happiest Baby letter supplies a direct example. Footnote 5 expressly cites FDA’s General Wellness guidance and concludes that the SNOO Hospital Bundle has neither a general-wellness intended use nor a low-risk profile. The footnote points to the underlying SNOO Smart Sleeper, an actively regulated device under 21 CFR 880.5690, and the risk of death or serious injury from inadequate securement. The hospital bundle and the authorized home-use configuration therefore need their actual uses and risks assessed separately [15].

BlephEx presents a different boundary. Its Class I, 510(k)-exempt classification under 878.4820/PYU was subject to the limitations in 878.9. The letter addresses claims outside that exemption and separately identifies missing GUDID submissions for the three devices. Those UDI duties were not created by the disease claims; device classification, exemption scope, intended use and applicable identification obligations each need their own assessment [14] [1] [2].

China SAMR Medical Device Advertising Governance: Order No. 21 Versus the May 2026 Draft Revision

China requires prior administrative review and approval for medical-device advertising within the applicable framework [7] [9]. On May 15, 2026, SAMR published the 48-article Administrative Measures for the Review and Release of Advertisements for Drugs, Medical Devices, Health Foods, and Foods for Special Medical Purpose (Draft for Comment) to replace the 34-article SAMR Order No. 21 (effective March 1, 2020) [7] [8] [9]. In June 2026, SAMR issued Announcement No. 20 of 2026 (Enforcement Guide on Advertising Citation Content / 《广告引证内容执法指南》), setting out substantiation rules for citations in commercial advertising [10].

Current Content Limits and the Proposed Extra-IFU Restriction

Order No. 21 Article 6 already ties device advertising to approved registration or filing documentation and the IFU. It already requires the contraindication/precaution statement when applicable and the personal-self-use warning for devices recommended for that use. Article 9 requires the advertising approval number; Article 10 requires prominent content to remain clearly legible and continuously displayed in video advertising [7].

The May 2026 draft would add prominent product-name display and expand the named product characteristics in Article 6 to include intended purpose and method of use. For audio advertisements, Draft Article 10 would require clear and complete spoken delivery of the content that must be prominently stated. These are proposed changes alongside existing obligations, so a planning checklist should identify which provisions already apply and which depend on adoption [9].

Draft Article 12(8) would expressly restrict theoretical citations and viewpoint statements outside the approved IFU. The official drafting explanation attributes this proposal to preventing deception and misleading consumers. If adopted in this form, the additional restriction would govern the cited theoretical or viewpoint content; it should not be represented as a current prohibition created by the consultation itself [9] [23].

Draft Article 36 Paragraph 3 proposes residual penalties for specified Article 12 items, including item (8), where the Advertising Law or other laws supply no penalty: correction plus a fine up to three times illegal gains, capped at RMB 30,000, or up to RMB 10,000 where there are no illegal gains. Paragraph 2 concerns a different set of listed items and refers to the corresponding Advertising Law provisions. These proposed provisions require their own scope check; a general description of deceptive advertising should not collapse the two paragraphs [9].

SAMR Announcement No. 20 of 2026 supplies a separate, cross-sectoral enforcement guide on advertising citations. It addresses truthfulness, accuracy, verifiability and source attribution, including the stated scope and validity of cited information. Depending on the material used, the guide also addresses testing-body qualifications and scientific sampling. It establishes substantiation expectations for a permitted citation rather than creating the proposed extra-IFU restriction in Draft Article 12(8) [10].

Digital Channel Governance: Live-Streams, E-Commerce Pages, and QR Codes

The May 2026 Draft Revision introduces specific articles addressing modern digital marketing channels [9] [23]:

• Live broadcasts, edited releases and platform responsibilities (Draft Articles 14–16): Article 14 addresses prohibited live-stream promotion, disguised advertising through health education and endorsements. Article 15 would exempt the specified real-time broadcasts by covered certificate/filing holders or producers/operators from review, subject to truthfulness, legality and Article 12 conditions. Recordings, clips or edits that form advertisements would require review before release. Article 16 would require platforms to monitor, intervene and retain records when violations are found; platforms providing paid traffic referral or similar promotion would bear advertising-operator/publisher responsibilities. Identify the entity, broadcast, later asset and commercial platform arrangement before applying a proposed allowance [9] [23].
• Required objective product displays (Draft Article 28): The proposed exception concerns information that applicable laws, administrative regulations, departmental rules or mandatory national standards require to be displayed, marked or disclosed. Eligible certificate/filing holders and production/operating enterprises would objectively display that information at their business premises or on product-sales pages of owned websites, official accounts, stores or applications. The listed information includes product name, appearance, price, specifications, grade, method of use, IFU and after-sales service. The exception is conditional on the required-disclosure purpose, eligible entity, location and actual content [9] [23].
• Linked destinations (current Order No. 72 Article 18; Draft Article 30): Article 18 of the Internet Advertising Measures, effective May 1, 2023, already requires advertisers, advertising operators and publishers to check advertising content at the next linked level that relates to the originating advertisement [24]. The draft would assign advertisers responsibility for the truthfulness and legality of linked content. Content at a linked destination that itself falls within advertising-review requirements would need the applicable review. Our operating recommendation is to record the checked destination and its revision history with the linking asset. The existing checking obligation and the proposed separate-review provision should each be assessed against the actual material [9] [23].
• Specified post-approval edits (Draft Article 31 Paragraph 2): Order No. 21 Article 20 is the current baseline for changing reviewed content. The draft proposes limited allowances for adjustments such as aspect ratio, font or background color, and specified commercial details such as price, address, store name, phone number or delivery method, subject to its conditions. Prominence, required disclosures and the Article 12 restrictions remain relevant. Teams can inventory these edit types for planning while checking the adopted rule before treating an allowance as operative [7] [9] [23].

Administrative clocks, existing numbering and the proposed validity floor

Administrative timelines and permit validity rules govern campaign planning under both regimes [7] [9].

The visual compares procedural clocks and proposed validity/cancellation changes. The content-side proposals above concern what is released; these administrative provisions affect the supporting application and continuing validity [7] [9].

Permit numbering is also an existing practice. SAMR’s 2020 document templates already used a six-digit group followed by five digits, and Beijing’s March 28, 2020 notice implemented the revised templates and numbering rules from April 1. Draft Article 47 would put the format into the revised measure, including media type and a YYMMDD expiry-date component. It should be described as codifying the format rather than inventing standardized numbering in 2026 [25] [9].

For a release record, store the issued approval number as an exact string, the corresponding decision and its actual validity date. A content system can display and flag that date, while the responsible applicant or reviewer determines continued validity and any cancellation action. Avoid calculating authorization solely from a number parser: the underlying product or production documentation and the applicable cancellation provisions still matter. Current Article 19 identifies specified revocation and cancellation triggers; Draft Article 24 would additionally address expiry without renewal and approved or filed product-attribute changes that make the advertisement inconsistent [7] [9].

As an operating recommendation, keep separate asset records for the live broadcast, recording and each edited release. Record the source, edits, destination, reviewer and publication date so the responsible team can determine which activity a decision covers.

A Practical Handoff for Approved Product Content

This section is VayoMed's operating recommendation. It is not a regulatory requirement, a legal opinion or a claim that VayoMed performs the client's regulatory review. The purpose is to keep approved content traceable when a device, model, indication, label or distribution arrangement changes.

Begin with the authoritative product record and its owner. Record the exact model/version and identifier, the applicable jurisdiction and the product evidence the reviewer used. Keep identity data separately from approved claim wording: a populated UDI record is useful for reconciliation, while a proposed intended-use or promotional change needs its own assessment. The relevant US obligations remain those in the actual labeling, intended-use and premarket provisions [1] [2] [3] [4]. Chinese advertising decisions require the applicable current product evidence and review framework, with the 2026 draft treated as a proposal [7] [9].

Before content release, assemble a bounded change package. It should identify the changed product fact, the pages and assets affected, the previous and proposed wording, the responsible reviewer and the planned effective date. Include distributor-facing material where the client controls or supplies it, with the client reviewer assessing attribution of independent third-party statements. For a video, preserve the reviewed script or transcript and the final released version; for a translated page, preserve the source revision and target review. These records support a reproducible handoff rather than a promise that software can decide the legal acceptability of a claim.

Choose the review route from the nature of the change. Correcting an approved product identifier, updating a factual model table, adding a new therapeutic claim and distributing scientific information about an unapproved use are different decisions. The FDA letters above illustrate why a reviewer must examine the actual product and evidence rather than treating all changes as copy edits. Any use of the January 2025 SIUU guidance must account for its stated implementation status; the unrevised display and later OMB approval notice need to be reconciled for the actual proposed workflow [20].

Release the approved version as one controlled update. Confirm that the public page, downloadable document, image caption, metadata and translated copy contain the intended revision. A content system can flag mismatched model strings or stale revisions; the client’s authorized reviewers assess the permissible indication and claim. Where a proposed SAMR draft exception or new permit-validity provision affects the plan, record its draft status and verify the adopted position before relying on it [8] [9].

After release, check the rendered asset and the actual destination of every substantive link. Record what went live, when, and which review it implements. If an approved claim is withdrawn or a product fact changes, use the same owner and revision record to identify the affected material. Escalation and withdrawal decisions stay with the client's authorized functions.

For context, the related VayoMed reports on FDA cleared versus approved language, general wellness and intended use and device recall communications address adjacent publishing decisions. They should be read for their declared scope, alongside the product’s actual review route.

Methodology and Limitations

The GUDID analysis uses the first four partitions of the July 7, 2026 archived openFDA device/udi export, normalized into CSV. They contain 1,000,000 records out of 5,083,948 rows in the archived export. Field-population checks test nonblank values in that projection. Assessment of submission completeness, authorization validity, marketed-product identity and intended-use accuracy requires further evidence beyond field presence. Five absent model/version values round to a 100.00% population rate; the precise count remains 999,995 [11].

The warning-letter analysis uses the July 31, 2026 archive. The FDA index subject screen is stated above; it selects 126 CDRH letters rather than all 224 CDRH letters. Regex matches are counted once per letter per term group. The existing cleanup attempts to isolate the letter body and remove agency URLs, but lexical matches still require interpretation. The 66-versus-60 comparison is descriptive; incidence, national manufacturer compliance and causation remain unmeasured. Part 812 terms appear in 37 subject-selected letters, so a role classification needs the recipient and narrative context [12].

The legal analysis separates current rules, draft text, nonbinding guidance and operating recommendations. The SAMR consultation draft is assessed as published on May 15, 2026, with an evidence cutoff of November 6, 2026 [8] [9]. The Chinese UDI discussion relies on the official system rules and declaration service [5] [6].

The six FDA letters are individual examples, not a representative comparison of manufacturers. Their allegations, product scope and cited provisions are assessed separately. A warning letter is an agency compliance communication, not a court judgment, and its relevance must be checked against the facts of the current product. Public record population and keyword matches are supporting observations; the article's conclusions rest on the actual provisions and checkable case evidence.

Conclusion

Keep identity, evidence and permission distinct. A DI or populated database field can help connect product records, but the client's reviewer still needs to assess the actual intended use and claim.

Use current and proposed rules differently. SAMR's May 2026 draft can inform preparation; its proposed effects should not be represented as current obligations. FDA guidance likewise needs its own status and scope checked.

Treat warning-letter aggregates as a route into the evidence. The cases show what an investigator actually examined; the recipient’s role and any marketing issue require the letter’s actual context.

Make the publishing handoff specific: product revision, approved wording, responsible owner, affected assets and released version. VayoMed's content work follows the client's regulatory and medical/legal review path. Contact VayoMed to discuss how that handoff fits an existing content operation.

Sources

1. U.S. Food and Drug Administration. 21 CFR Part 801, Subpart B — Labeling Requirements for Unique Device Identification. Title 21, Code of Federal Regulations, Chapter I, Subchapter H (governing plain-text and machine-readable AIDC UDI labeling under § 801.40 and direct marking under § 801.45).

2. U.S. Food and Drug Administration. 21 CFR Part 830 — Unique Device Identification. Title 21, Code of Federal Regulations, Chapter I, Subchapter H (governing UDI requirements under Subpart B, issuing agency accreditation under Subpart C, and GUDID submission mandates under Subpart E, §§ 830.300–830.360).

3. U.S. Food and Drug Administration. 21 CFR § 801.4 — Meaning of Intended Uses. Title 21, Code of Federal Regulations, Chapter I, Subchapter H (establishing objective intent through labeling claims, commercial advertising, and oral or written statements by the labeler or its representatives).

4. U.S. Food and Drug Administration. 21 CFR Part 807, Subpart E — Premarket Notification Procedures (21 CFR § 807.81). Title 21, Code of Federal Regulations, Chapter I, Subchapter H (specifying when a 510(k) premarket notification is required for significant modifications in design, material, manufacturing, or intended use).

5. National Medical Products Administration. Medical Device Unique Device Identification System Rules, Announcement No.66 of 2019, signed August 23, published August 27, 2019 and effective October 1, 2019.

6. National Medical Products Administration. Medical device product-identifier declaration: official service guide, legal basis and responsible registrant/filing-entity submission.

7. State Administration for Market Regulation (SAMR) of China. Interim Administrative Measures for the Review and Release of Advertisements for Drugs, Medical Devices, Health Foods, and Foods for Special Medical Purpose (SAMR Order No. 21). Promulgated December 24, 2019; effective March 1, 2020 (binding legal framework governing medical device advertising review, application procedures, and content limits across 34 articles).

8. State Administration for Market Regulation (SAMR) of China. Public Consultation Notice on the Draft Revision of the Administrative Measures for the Review and Release of Advertisements for Drugs, Medical Devices, Health Foods, and Foods for Special Medical Purpose. Published May 15, 2026 (announcing public comment window through June 15, 2026 for the proposed 48-article advertising measures revision).

9. State Administration for Market Regulation (SAMR) of China. Administrative Measures for the Review and Release of Advertisements for Drugs, Medical Devices, Health Foods, and Foods for Special Medical Purpose (Draft for Comment, May 15, 2026). Consultation draft comprising 48 articles governing medical device advertising content, the ban on extra-IFU theoretical citations (Draft Article 12(8)), live-stream video replays (Draft Article 15), 24-month validity floor (Draft Article 23), owned e-commerce display exemptions (Draft Article 28), and QR/link liability (Draft Article 30).

10. State Administration for Market Regulation (SAMR) of China. Announcement No. 20 of 2026 — Enforcement Guide on Advertising Citation Content (广告引证内容执法指南). Signed June 3, 2026; published June 12, 2026 (establishing substantiation, scientific sampling, and attribution rules for third-party research and data citations in commercial advertising).

11. U.S. Food and Drug Administration. openFDA device/udi data and downloads. Authors’ analysis of the archived July 7, 2026 export: 5,083,948 normalized rows across 21 partitions; first four partitions, 1,000,000 records, screened for nonblank fields. This is a historical ordered sample.

12. U.S. Food and Drug Administration. Warning Letters database. Authors’ analysis of the July 31, 2026 indexed snapshot: 3,643 total letters, 224 CDRH letters; 126 selected by the stated manufacturing/registration/reporting subject screen.

13. U.S. Food and Drug Administration. GUDID Data Elements Reference Table, XLSX with latest ChangeLog entry December 17, 2024, retrieved November 6, 2026 through FDA’s UDI technical-document index. Device Description is recommended, rather than a required data element, and is identified as important for identification and adoption.

14. U.S. Food and Drug Administration, Center for Devices and Radiological Health. Warning Letter to BlephEx, LLC (MARCS-CMS 725861, June 3, 2026). Warning letter citing Section 501(f)(1)(B), Section 502(o), 21 CFR 807.81(a), Section 502(t)(2), 21 CFR 801.20(a), and 21 CFR §§ 830.300(a) / 830.320(b) for website clinical videos exceeding Class I 510(k) exemption boundaries and failure to submit required device identifiers to GUDID.

15. U.S. Food and Drug Administration, Center for Devices and Radiological Health. Warning Letter to Happiest Baby, Inc. (MARCS-CMS 718306, June 15, 2026). Warning letter citing Section 501(f)(1)(B), Section 502(o), and 21 CFR 807.81(a)(3)(i) and (ii) for commercial e-commerce distribution of unauthorized X-Small (4–8 lbs, 44 cm x 21 cm) and X-Large sleep sacks outside De Novo authorization DEN210039, noting risk of vital organ compression and respiratory compromise.

16. U.S. Food and Drug Administration, Center for Devices and Radiological Health. Warning Letter to BMC Medical Co., Ltd. (MARCS-CMS 725759, May 20, 2026). Warning letter citing Section 502(o) and 21 CFR 807.81(a)(3)(i) for unsubmitted firmware algorithm updates (version 2.11.01), sound-abatement material modifications, PCBA redesign, and commercial rebranding of the cleared Luna CPAP (K153387) to G3X APAP.

17. U.S. Food and Drug Administration, Center for Devices and Radiological Health. Warning Letter to Diasol, Inc. (MARCS-CMS 719460, January 29, 2026). Warning letter citing Section 501(f)(1)(B), Section 502(o), 21 CFR 807.81(a)(3)(ii), Section 502(c), 21 CFR 801.20(a), and 21 CFR 820.80(d) for unapproved machine disinfection indications and missing plain-text/AIDC UDI labeling across six dialysate concentrate products during on-site inspection.

18. U.S. Food and Drug Administration, Center for Devices and Radiological Health. Warning Letter to Physitemp Instruments, LLC (MARCS-CMS 717394, November 12, 2025). Warning letter citing Section 502(c), Section 502(t)(2), 21 CFR 801.20(a), 21 CFR 801.40(a)(1)–(2), and 21 CFR 820.75(a) for missing plain-text and machine-readable AIDC UDI labels across ten clinical temperature monitoring consoles and probes and total absence of GUDID submissions.

19. U.S. Food and Drug Administration, Center for Devices and Radiological Health. Warning Letter to Technological Medical Advancements LLC (MARCS-CMS 712715, September 26, 2025). Warning letter citing Section 501(f)(1)(B) and Section 502(o) for marketing Diowave 250 WLS and 100 WLS High Power Laser Systems for unapproved indications beyond K121363 on company website, and citing Section 502(c), 21 CFR 801.20(a), and 21 CFR 801.40(a) for distributing Diowave Pure Pulse Laser System devices lacking required UDI labeling.

20. U.S. Food and Drug Administration. Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers — Guidance for Industry (Revision 2). Final Guidance, issued January 2025 (Docket No. FDA-2008-D-0053, Federal Register Doc. 2024-31539; marked 'Not for Current Implementation' pending OMB PRA review; articulating agency enforcement policy regarding 21 CFR 801.4).

21. U.S. Food and Drug Administration. General Wellness: Policy for Low Risk Devices — Guidance for Industry and Food and Drug Administration Staff. Final Guidance, updated January 6, 2026 (Docket No. FDA-2014-N-1039; outlining criteria for enforcement discretion for low-risk wellness products and explaining general-wellness intended-use criteria and the separate low-risk assessment, including invasiveness, implantation and risks requiring specific regulatory controls).

22. FDA. Agency Information Collection Activities; Announcement of OMB Approvals, 90 FR 46225, September 25, 2025, FR Doc. 2025-18621. Docket FDA-2008-D-0053; OMB control numbers 0910-0686 and 0910-0485 approvals through July 31, 2028.

23. State Administration for Market Regulation (SAMR) of China. Official Drafting Explanation for the Administrative Measures for the Review and Release of Advertisements for Drugs, Medical Devices, Health Foods, and Foods for Special Medical Purpose (Draft for Comment, May 15, 2026). Regulatory rationale explaining the prevention of misleading theoretical claims, live-stream governance, e-commerce factual display exemptions, and minimum 2-year permit validity adjustments.

24. SAMR. Internet Advertising Measures, Order No. 72, Article 18. Effective May 1, 2023.

25. Beijing Medical Products Administration. Notice on standardizing drug and medical-device advertising review, March 28, 2020. Implements SAMR’s 2020 templates and numbering rules from April 1; includes permit-number template.